Icosavax Inc. (ICVX)
15.31
-0.14 (-0.91%)
At close: Feb 16, 2024, 9:00 PM
-0.91% (1D)
| Bid | n/a |
| Market Cap | 769.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -92.62M |
| EPS (ttm) | -2.2 |
| PE Ratio (ttm) | -6.959090909090909 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 8,556,852 |
| Avg. Volume (20D) | 1,053,296 |
| Open | 15.40 |
| Previous Close | 15.45 |
| Day's Range | 15.28 - 15.44 |
| 52-Week Range | 4.75 - 16.11 |
| Beta | 1.28 |
About ICVX
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumo...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 60
Stock Exchange NASDAQ
Ticker Symbol ICVX
Website https://icosavax.com